Project Grant HT94252410128
Award Date
3/1/24
Completion Date
2/28/27
Dollars Obligated
$555K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14228, USA
Similar Awards
This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,710,727.00 in funding to Health Research, Inc. (a non-profit organization) to conduct research on targeting the BRSK2 gene in aggressive breast cancer brain metastasis. The award period runs from Sep 30, 2024 to Sep 29, 2027. As a prime grantee, Health Research, Inc. will leverage its expertise in cancer biology, immunotherapy development, and biomarker...
The Defense Health Agency awarded $780,749 to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research into novel combination immune therapy regimens for metastatic breast cancer. The three-year project grant, beginning February 1, 2023, will fund the development of innovative medical solutions through basic, applied, and advanced biomedical research. Specifically, the awardee will investigate new...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
This $1,301,250.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research to inhibit myeloid-derived suppressor cell (MDSC) biogenesis and thereby enhance the efficacy of immunotherapy in triple-negative breast cancer. The award recipient is Health Research, Inc., a non-profit research organization based in Buffalo, New York, which will conduct this research over a 3-year period from March 1, 2025 to February...
This federal Project Grant award, valued at $808,141.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award aims to advance research targeting inflammatory pathways in breast cancer brain metastases, with the goal of treating edema and radiation necrosis using anti-VEGF ultrasmall particle therapy. The grant recipient is the Weill Medical College of Cornell University, a prominent academic medical institution with...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
This federal Project Grant award, valued at $672,694 and awarded by the Defense Health Agency, supports research at Brown University focused on the "Optimization of RNA LNPs for the Generation of Cellular Immunity in Metastatic Breast Cancer." The research is funded through the Military Medical Research and Development (CFDA 12.420) federal grant program, which supports advanced biomedical research initiatives with the potential to transform healthcare for military service members...
This $998,436 Project Grant was awarded on July 1, 2023 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant was awarded to The Research Foundation for the State University of New York (RF SUNY) to study the molecular mechanisms and therapeutic potential of heparan sulfate proteoglycans in remyelination. This 3-year research project aims to transform health care for Service Members and the American public through innovative and...
The federal Project Grant award, valued at $728,450.00 and provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research conducted by the Cold Spring Harbor Laboratory (CSHL) on the communication between cancer-associated fibroblasts and neurons, and how this interaction promotes the progression of pancreatic cancer. The award, which runs from July 1, 2025 to June 30, 2028, will enable CSHL to carry out advanced biomedical...